The month also brought conversions to full approval for Retevmo and Sirturo

With UCB patent cliff looming, Zogenix takeout comes ahead of possible Fintepla label expansion

Companies dial in subtype selectivity, explore new modalities, and move to more homogeneous trial populations

BioCentury’s roundup of translational news

Why companies should invest in data, alliances to support pediatric extrapolation